TrialClinical and translational science2025

Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.

Yi-Chung Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.